Navigation Links
China YCT International Group, Inc. Announces That the State Intellectual Property Office of the People's Republic of China has Approved a Patent to its Operating Subsidiary, Shandong Spring Pharmaceutical Co. Ltd.
Date:1/25/2010

SHANDONG, China, Jan. 25 /PRNewswire-Asia-FirstCall/ -- China YCT International Group, Inc. ("China YCT" or the "Company") (OTC Bulletin Board: CYIG) today announced that on December 23, 2009 the State Intellectual Property Office of the People's Republic of China approved the patent application of its operating subsidiary, Shandong Spring Pharmaceutical Co., Ltd., for "a unique method of making ginkgo tea, and the manufacturing technology." This patent represents a key addition to the Company's growing intellectual property portfolio.

China YCT's technology improves the methods traditionally employed in the gingko tea health care products industry, and provides a faster, more efficient method of offering the public gingko tea. Studies have shown that Gingko tea has memory-enhancing benefits for people. "Our method of producing gingko tea increases the memory-enhancing ingredients as compared to the traditional gingko products, so our products will provide increased resistance to memory loss, whether short- or long-term," said Mr. Tinghe Yan, Chairman and CEO of China YCT.

The Company's new products can slow down the platelet activating factor (PAF) to stop it from over stimulation. Medical studies have shown that excess production of PAF can result in various inflammation-related diseases, including damage to the brain. In addition, like all other properly made gingko tea products, the Company's new products help reduce cholesterol and aid in blood circulation, thus reducing the risk of heart disease.

In order to maximize the benefits of gingko, the Company's R&D team developed a new and unique production method. "Our unique new gingko tea products, which will provide many physical benefits to people that other gingko teas cannot, give us confidence that we can make successful inroads into China's healthcare market in the years ahead," said Mr. Tinghe Yan.

"Receiving this patent is another important milestone, as China YCT accelerates its strategic growth plan," said Mr. Yan. "We're committed to developing innovative products based on our experience in the gingko healthcare products industry. We intend this to be the first in a series of technological breakthroughs, and we will continue to seek legal protection for these innovations. The benefits of our new products enhance the value of the Company as a whole," Mr. Yan added.

About China YCT International Group, Inc.

Established in 2005, China YCT International Group, Inc., through its operating subsidiary, Shandong Spring Pharmaceutical Co. Ltd., a corporation organized under the laws of the People's Republic of China, is a high-tech enterprise, which applies modern biological technology and integrates research & development, production and sales of ginkgo healthcare products, ginkgo cosmetics, daily-use chemical products, ginkgo glycoside products and biological medicines.

Safe Harbor Statement

The statements contained herein that are not historical facts are "forward-looking statements" within the meaning of Section 21E of the Securities and Exchange Act of 1934, as amended, and the Private Securities Litigation Reform Act of 1995. Such forward-looking statements may be identified by, among other things, the use of forward-looking terminology such as "believes," "expects," "may," "will," "should" or "anticipates" or the negative thereof or other variations thereon or comparable terminology, or by discussions of strategy that involve risks and uncertainties. In particular, our statements regarding the potential growth of the markets are examples of such forward-looking statements. The forward-looking statements include risks and uncertainties, including but not limited to, general economic conditions and regulatory developments, not within our control. The factors described from time to time in our filings with the Securities and Exchange Commission under the heading "Risk Factors" could cause actual results and developments to be materially different from those expressed or implied by such statements. The forward-looking statements are made only as of the date of this press release, and we undertake no obligation to publicly update such forward- looking statements to reflect subsequent events or circumstances.

    For further information, contact:

     Zecheng Shao
     Phone: +86-537-426-8260
     Fax:   +86-537-426-8292

SOURCE China YCT International Group, Inc.


'/>"/>
SOURCE China YCT International Group, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. China Yongxin Pharmaceuticals Opened Three New Stores in 2009 and Expanded Customer Base
2. China Yongxin Pharmaceuticals Projects Higher Net Income and EPS on Reduced Revenue for Full-Year 2009
3. China Cord Blood Corporation Announces Partial Exercise of Over-Allotment Option
4. Sinovacs CEO Weidong Yin Presented with Annual Innovation Award by China Central Television
5. American Oriental Bioengineering Announces the Inclusion of 158 Drugs in Chinas National Insurance Catalog
6. China Sky Medical, Inc. Has 30 Medicines that will Be Included in Chinas National Insurance Directory
7. China Biologic Products to Ring NASDAQ Opening Bell
8. Simcere Announces 105 Drugs Included in Chinas National Drug Reimbursement List
9. Pharma and Biotech Leaders to Converge in China at Asia Pharma R&D Leaders 2010 Summit
10. Shanghai ChemPartner Ranks 3rd among 2009 Deloitte Technology Fast 50 China Winning Companies
11. China Sky One Medical, Inc. Signs Distribution Agreement with MDK for the Sale of Two Diagnostic Kits in Southeast Asia
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/26/2017)... , ... April 26, 2017 , ... ... teamed up with NASA to showcase the future of deep space exploration and ... (SLS) rocket and Orion spacecraft and includes a guest appearance by former Shuttle ...
(Date:4/26/2017)... ... April 26, 2017 , ... As ... conversations among healthcare industry stakeholders, the discussion surrounding the topic will continue at ... 15-18, 2017 in Los Angeles, Calif. Hosted by the Workgroup for Electronic Data ...
(Date:4/25/2017)... 2017 Providence -based ... novel immune-modulating technology to an undisclosed global pharmaceutical company, ... Tregitopes, pronounced T·rej·itopes, are a set of ... CEO Annie De Groot and EpiVax ... an autoimmune disease therapy, Tregitopes are capable of ...
(Date:4/24/2017)... , April 24, 2017  Dante Labs announced today ... only EUR 850 (ca. $900). While American individuals have been ... first time Europeans can access WGS below EUR 1,000. ... crucial to leveraging genetic information to make informed decisions about ... ...
Breaking Biology Technology:
(Date:4/11/2017)... April 11, 2017 Crossmatch®, a globally-recognized ... solutions, today announced that it has been awarded ... Projects Activity (IARPA) to develop next-generation Presentation Attack ... "Innovation has been a driving force within ... will allow us to innovate and develop new ...
(Date:4/11/2017)... 2017 NXT-ID, Inc. (NASDAQ:   NXTD ... the appointment of independent Directors Mr. Robin D. Richards ... of Directors, furthering the company,s corporate governance and expertise. ... Gino Pereira , Chief ... to their guidance and benefiting from their considerable expertise as ...
(Date:4/5/2017)... April 5, 2017 Today HYPR Corp. ... the server component of the HYPR platform is officially ... the end-to-end security architecture that empowers biometric authentication across ... has already secured over 15 million users across the ... of connected home product suites and physical access represent ...
Breaking Biology News(10 mins):